Vectorite Biomedical Inc. (TPEX:4170)
Taiwan
· Delayed Price · Currency is TWD 13.75
-0.05 (-0.36%)
Apr 29, 2026, 1:57 PM CST
Vectorite Biomedical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 25.71 | 30.6 | 25.32 | 27.87 | 39.2 | Upgrade
|
| Short-Term Investments | 144.9 | - | - | 179.7 | 154.5 | Upgrade
|
| Trading Asset Securities | - | 154.3 | 178.36 | 5.94 | 45.68 | Upgrade
|
| Cash & Short-Term Investments | 170.61 | 184.9 | 203.67 | 213.52 | 239.38 | Upgrade
|
| Cash Growth | -7.73% | -9.21% | -4.61% | -10.80% | 167.28% | Upgrade
|
| Accounts Receivable | 2.77 | 6.11 | 5.64 | 5.59 | 1.11 | Upgrade
|
| Other Receivables | 0.42 | 0.46 | 0.06 | 0.16 | 0.76 | Upgrade
|
| Receivables | 3.19 | 6.56 | 5.69 | 5.75 | 1.87 | Upgrade
|
| Inventory | 14.97 | 14.79 | 10.04 | 4.83 | 7.24 | Upgrade
|
| Prepaid Expenses | 3.1 | 2.22 | 3.73 | 7.97 | 1.84 | Upgrade
|
| Other Current Assets | 0.01 | - | - | - | - | Upgrade
|
| Total Current Assets | 191.89 | 208.47 | 223.13 | 232.06 | 250.32 | Upgrade
|
| Property, Plant & Equipment | 172.7 | 172.4 | 178.33 | 182.73 | 190.7 | Upgrade
|
| Long-Term Investments | 142.62 | 15.5 | 23.33 | 23.4 | 24.24 | Upgrade
|
| Other Intangible Assets | 0.41 | 6.04 | 21.81 | 22.54 | 22.54 | Upgrade
|
| Other Long-Term Assets | 1.93 | 10.36 | 5.51 | 5.1 | 4.85 | Upgrade
|
| Total Assets | 509.56 | 412.78 | 452.1 | 465.82 | 492.65 | Upgrade
|
| Accounts Payable | 0.92 | 1.14 | 1.2 | 3.18 | 2.72 | Upgrade
|
| Accrued Expenses | - | 6.05 | 7.02 | 4.85 | 6.39 | Upgrade
|
| Current Unearned Revenue | 4.51 | 5.31 | 3.13 | 5.25 | 5.89 | Upgrade
|
| Other Current Liabilities | 10.76 | 2.33 | 1.38 | 2.27 | 1.61 | Upgrade
|
| Total Current Liabilities | 16.19 | 14.83 | 12.73 | 15.55 | 16.61 | Upgrade
|
| Long-Term Leases | 0.21 | - | - | - | - | Upgrade
|
| Long-Term Unearned Revenue | 8.07 | 8.16 | 8.51 | 8.93 | 9.09 | Upgrade
|
| Other Long-Term Liabilities | 0.01 | 0.21 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Total Liabilities | 24.48 | 23.2 | 21.25 | 24.49 | 25.71 | Upgrade
|
| Common Stock | 437.71 | 437.71 | 437.71 | 721.4 | 721.4 | Upgrade
|
| Additional Paid-In Capital | 11.67 | 11.67 | 11.67 | 101.14 | 101.14 | Upgrade
|
| Retained Earnings | 49.52 | -46.65 | -6.6 | -373.17 | -346.75 | Upgrade
|
| Comprehensive Income & Other | -14.19 | -13.56 | -12.34 | -8.48 | -9.29 | Upgrade
|
| Total Common Equity | 484.71 | 389.16 | 430.44 | 440.9 | 466.51 | Upgrade
|
| Minority Interest | 0.37 | 0.42 | 0.41 | 0.44 | 0.43 | Upgrade
|
| Shareholders' Equity | 485.08 | 389.58 | 430.85 | 441.34 | 466.94 | Upgrade
|
| Total Liabilities & Equity | 509.56 | 412.78 | 452.1 | 465.82 | 492.65 | Upgrade
|
| Total Debt | 0.21 | - | - | - | - | Upgrade
|
| Net Cash (Debt) | 170.4 | 184.9 | 203.67 | 213.52 | 239.38 | Upgrade
|
| Net Cash Growth | -7.84% | -9.21% | -4.61% | -10.80% | 167.28% | Upgrade
|
| Net Cash Per Share | 3.88 | 4.23 | 4.65 | 4.88 | 5.57 | Upgrade
|
| Filing Date Shares Outstanding | 43.66 | 43.77 | 43.77 | 43.77 | 43.77 | Upgrade
|
| Total Common Shares Outstanding | 43.66 | 43.77 | 43.77 | 43.77 | 43.77 | Upgrade
|
| Working Capital | 175.7 | 193.64 | 210.4 | 216.52 | 233.71 | Upgrade
|
| Book Value Per Share | 11.10 | 8.89 | 9.83 | 10.07 | 10.66 | Upgrade
|
| Tangible Book Value | 484.3 | 383.12 | 408.63 | 418.36 | 443.97 | Upgrade
|
| Tangible Book Value Per Share | 11.09 | 8.75 | 9.34 | 9.56 | 10.14 | Upgrade
|
| Land | - | 59.45 | 59.45 | 59.45 | 59.45 | Upgrade
|
| Buildings | - | 157.27 | 155.36 | 155.36 | 155.36 | Upgrade
|
| Machinery | - | 60.92 | 59.99 | 55.23 | 54.34 | Upgrade
|
| Leasehold Improvements | - | 2.5 | 2.5 | 2.5 | 2.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.